Publikationen

Priv.-Doz. Dr. Ilja Spellmann

Originalarbeiten

  • Riedel M, Musil R, Spellmann I, Seemüller F and Möller HJ (2018):
    Quetiapine XR – A New Retard Formulation in the Treatment of Schizophrenia, Pharmacopsychiatry
  • Riedel M, Schwarz MJ, Strassnig M, Spellmann I, Müller-Arends A, Weber K et al. Risperidone plasma levels, clinical response and side-effects. Eur Arch Psychiatry Clin Neurosci 2005; 255:261-268.
  • Schwarz MJ, Krönig H, Riedel M, Dehning S, Douhet A, Spellmann I, Ackenheil M, Möller HJ, Müller N. IL-2 and IL-4 polymorphisms as candidate genes in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2006 Mar;256(2):72-6.
  • Riedel M, Müller N, Strassnig M, Spellmann I, Engel RR, Musil R et al. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci 2005; 255:432-437.
  • Riedel M, Spellmann I, Schwarz MJ, Strassnig M, Sikorski C, Möller HJ et al. Decreased T cellular immune response in schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 2006; 256: 72-76.
  • de la Fontaine L, Schwarz MJ, Riedel M, Dehning S, Douhet A, Spellmann I et al. Investigating disease susceptibility and the negative correlation of schizophrenia and rheumatoid arthritis focusing on MIF and CD14 gene polymorphisms. Psychiatry Res 2006; 144: 39-47.
  • Müller N, Schwarz MJ, Dehning S, Douhet A, Cerovecki A, Goldstein-Müller B Spellmann I, Hetzel G, Maino K, Kleindienst N, Möller HJ, Arolt V, Riedel M. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006; 11:680-684.
  • Meisenzahl EM, Scheuerecker J, Zipse M, Ufer S, Wiesmann M, Frodl T, Koutsouleris N, Zetzsche T, Schmitt G, Riedel M, Spellmann I, Dehning S, Linn J, Brückmann H, Möller HJ. Effects of treatment with the atypical neuroleptic quetiapine on working memory function: a functional MRI follow-up investigation. Eur Arch Psychiatry Clin Neurosci 2006; 256: 522-531.
  • Riedel M, Spellmann I, Strassnig M, Douhet A, Dehning S, Opgen-Rhein M et al. Effects of Risperidone and Quetiapine on Cognition in Patients with Schizophrenia and Predominantly Negative Symptoms. Eur Arch Psychiatry Clin Neurosci 2007; 257: 360-370.
  • Riedel M, Müller N, Spellmann I*, Engel R R, Opgen-Rhein M, Valdevit R, Dehning S et al. Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia.Eur Arch Psychiatry Clin Neurosci 2007; 257: 402-12.
  • Musil R, Spellmann I, Riedel M, Dehning S, Douhet A, Maino K et al. SNAP-25 gene polymorphisms and weight gain in schizophrenic patients. J Psychiatr Res 2008; 42: 963-970.
  • Spellmann I, Riedel M, Musil R, Douhet A, Dehning S, Zill P, Müller N, Möller H-J, Bondy B. Associations of SNAP-25 polymorphisms with cognitive dysfunctions in Caucasian patients with schizophrenia during a brief trail of treatment with atypical antipsychotics. Eur Arch Psychiatry Clin Neurosci 2008; 258: 335-344.
  • Dehning, S, Müller N, Matz J, Bender A, Kerle I, Benninghoff J, Musil R, Spellmann I, Bondy B, Möller HJ, Riedel M, Zill P. A genetic variant of HTR2C may play a role in the manifestation of Tourette syndrome. Psychiatr Genet 2010; 20: 35-38.
  • Riedel M, Spellmann I, Schennach-Wolff R, Musil R, Dehning S, Cerovecki A, Opgen-Rhein M, Matz, J, Seemüller, F, Obermeier M, Severus E, Engel RR, Müller N, Möller HJ. Effect of Aripiprazole on Cognition in the Treatment of Patients with Schizophrenia. Pharmacopsychiatry 2010 Mar;43(2):50-7.
  • Riedel M, Schennach-Wolff R, Musil R, Dehning S, Cerovecki A, Opgen-Rhein M, Matz J, Seemüller F, Obermeier M, Engel RR, Müller N, Möller HJ, Spellmann I. Neurocognition and its influencing factors in the treatment of schizophrenia-effects of aripiprazole, olanzapine, quetiapine and risperidone. Pharmacopsychiatry 2010 Mar;43(2):50-7.
  • Spellmann I, Rujescu D, Musil R, MayrA, Giegling I, GeniusJ, Zill P, Dehning S,  Opgen-Rhein M,  Cerovecki A, Hartmann AM, SchäferM, Bondy B,Müller N, Möller HJ, Riedel M. Homer-1 polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients. J Psychiatr Res 2011 Feb;45(2):234-41.
  • Riedel M, Spellmann I, Schennach-Wolff R, Obermeier M, Musil R. The RSM-scale: a pilot study on a new specific scale for self- and observer-rated quality of life in patients with schizophrenia. Qual Life Res 2011 Mar;20(2):263-72.
  • Riedel M, Severus E, Schennach-Wolff R, Musil R, Spellmann I, Oppolzer B, Möller HJ, Köhler J, Seemüller F. Effectiveness of quetiapine in outpatients with schizophrenia assessed under "real-life" conditions: a German clinical-practice evaluation programme. J Clin Psychopharmacol 2011 Feb;31(1):120-2.                Seemüller F, Riedel M, Obermeier M, Schennach-Wolff R, Spellmann I, Meyer S, Bauer M, Adli M, Kronmüller K, Ising M, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Möller HJ. The validity of self-rated psychotic symptoms in depressed inpatients. Eur Psychiatry 2011 Mar 8.
  • Musil R, Schwarz MJ, Riedel M, Dehning S, Cerovecki A, Spellmann I, Arolt V,  Müller N. Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression--no influence of celecoxib treatment. J Affect Disord 2011 Nov;134 (1-3): 217-25.
  • Schennach R, Zill P, Obermeier M, Hauer D, Dehning S, Cerovecki A, Opgen-Rhein M, Musil R, Spellmann I, Matz J, Krause D, Seemüller F, Müller N, Möller HJ, Bondy B, Riedel M. The CNR1 gene in depression and schizophrenia - is there an association with early improvement and response? Psychiatry Res. 2012 Mar 30;196(1):160. 
  • Spellmann I, Riedel M, Schennach-Wolff R, Seemüller F, Obermeier M, Musil R, Jäger M, Schmauß M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Möller HJ. One-year functional outcomes of naturalistically treated patients with schizophrenia. Psychiatry Res. 2012 Aug 15;198(3):378-85. 
  • Musil R, Zill P, Seemüller F, Bondy B, Obermeier M, Spellmann I, Bender W, Adli M, Heuser I, Zeiler J, Gaebel W, Maier W, Rietschel M, Rujescu D, Schennach R, Möller HJ, Riedel M. No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression. Eur Arch Psychiatry Clin Neurosci. 2013 Aug;263(5):405-12.
  • Musil R(1), Zill P, Seemüller F, Bondy B, Meyer S, Spellmann I, Bender W, Adli M, Heuser I, Fisher R, Gaebel W, Maier W, Rietschel M, Rujescu D, Schennach R, Möller HJ, Riedel M. Genetics of emergent suicidality during antidepressive treatment-data from a naturalistic study on a large sample of inpatients with a major depressive episode. Eur Neuropsychopharmacol. 2013 Jul;23(7):663-74.   
  • Spellmann I, Rujescu D, Musil R, Meyer S, Giegling I, Genius J, Zill P, Dehning S, Cerovecki A, Seemüller F, Schennach R, Hartmann AM, Schäfer M, Müller N, Möller HJ, Riedel M. Pleckstrin homology domain containing 6 protein (PLEKHA6) polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jun 3;51:190-5.
  • Hamann J, Lipp ML, Christ-Zapp S, Spellmann I, Kissling W. Psychiatrist and patient responses to suspected medication nonadherence in schizophrenia spectrum disorders. Psychiatr Serv. 2014 Jul;65(7):881-7.
  • Schennach R, Riedel M, Obermeier M, Spellmann I, Musil R, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Möller HJ. What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial. Eur Arch Psychiatry Clin Neurosci. 2015 Mar;265(2):107-16.
  • Schennach R, Möller HJ, Obermeier M, Seemüller F, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Musil R, Spellmann I, Riedel M. Challenging the understanding of significant improvement and outcome in schizophrenia - the concept of reliable and clinically significant change methods. Int J Methods Psychiatr Res. 2016 Mar;25(1):3-11. 
  • Spellmann I, Schennach R, Seemüller F, Meyer S, Musil R, Jäger M, Schmauß M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Bauer M, Adli M, Zeiler J, Bender W, Kronmüller KT, Ising M, Brieger P, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Riedel M, Möller HJ. Validity of remission and recovery criteria for schizophrenia and major depression: comparison of the results of two one-year follow-up naturalistic studies. Eur Arch Psychiatry Clin Neurosci. 2016 Oct 26. 
  • Spellmann I, Riedel M, StädtlerJ, Zill P, Obermeier M, Cerovecki A, Dehning S, Schennach R, Epple M, Opgen-Rhein M, Müller N, Bondy B, Möller HJ, Musil R. Associations of NEUROD2 polymorphisms and change of cognitive dysfunctions in schizophrenia and schizoaffective disorder after eight weeks of antipsychotic treatment. Cogn Neuropsychiatry. 2017 May 4:1-18. 
  • Schennach R, Obermeier M, Seemüller F, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Spellmann I, Musil R, Möller HJ, Riedel M. Add-on Antidepressants in the Naturalistic Treatment of Schizophrenia Spectrum Disorder - When, Who, and How? Pharmacopsychiatry. 2017 May 15. 
  • SpellmannI, ReinhardM, Veverka D, ZillP, ObermeierM, DehningS, SchennachR, MüllerN, MöllerHJ, RiedelM, Musil R.QTc prolongation in short-term treatment of schizophrenia patients - effects of different antipsychotics and genetic factors. Eur Arch Psychiatry Clin Neurosci.2018 Feb 10. 
  •  Musil R, Seemüller F, Meyer S, Spellmann I, Adli M, Bauer M Kronmüller KT, Brieger P, Laux G, Bender W, Heuser I, Fisher R, Gaebel W, Schennach R, Möller HJ, Riedel M. Subtypes of depression and their overlap in a naturalistic inpatient sample of major depressive disorder. Int J Methods Psychiatr Res. 2018 Mar; 27(1). 
  • Schennach R, Riedel M, Spellmann I, Musil R, Obermeier M, Jäger M, Bottlender R, Schmauss M, Laux G, Möller HJ. Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled Study. Pharmacopsychiatry. 2019 Jul;52(4):180-185. 
  • Kirchner SK, Ozkan S, Musil R, Spellmann I, Kannayian N, Falkai P, Rossner M, Papiol S. Polygenic analysis suggests the involvement of calcium signaling in executive function in schizophrenia patients. Eur Arch Psychiatry Clin Neurosci. 2018 Dec 7.
  • Schennach R, Obermeier M, Spellmann I, Seemüller F, Musil R, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Bauer M, Adli M, Zeiler J, Bender W, Kronmüller KT, Ising M, Brieger P, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Möller HJ, Riedel M. Remission in schizophrenia - What are we measuring? Comparing the consensus remission criteria to a CGI-based definition of remission and to remission in major depression. Schizophr Res. 2019 Jul;209:185-192. 
  • Schennach R, Riedel M, Obermeier M, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Seemüller F, Spellmann I, Musil R, Möller HJ. What happens with schizophrenia patients after their discharge from hospital? Results on outcome and treatment from a "real-world" 2-year follow-up trial. Eur Arch Psychiatry Clin Neurosci. 2019 Aug 28.

Buchbeiträge und Übersichtsarbeiten

  • Riedel M, Spellmann I, Severus E, Müller N, Möller HJ. Das Antipsychotikum Quetiapin in der Behandlung der Schizophrenie. Die Psychiatrie 2005; 1:55-68. 
  • Riedel M, Spellmann I, Müller N, Möller HJ. Das Antipsychotikum Ziprasidon in der Behandlung der Schizophrenie. Die Psychiatrie 2005; 3:179-194.
  •  Riedel M, Spellmann I. Quetiapin in der Behandlung der Negativsymptome. In: Möller HJ, (Hrsg.). Das Quetiapin-Dossier 2005; 75-94.
  • RiedelM, MüllerN, StrassnigM, Spellmann I, SeverusE, MöllerHJ. Quetiapine in the treatment of schizophrenia and related disorders. Neuropsychiatr Dis Treat 2007; 3: 219-235.
  • Bondy B, Spellmann I. Pharmacogenetics of antipsychotics: useful for the clinician? Curr Opin in Psychiatr 2007; 20:126-130. 
  • Riedel M, Spellmann I, Müller N, Möller HJ. Schizophrenic patients in the family practice. MMW Fortschr Med 2007; 149 Suppl 2: 98-101.
  • Riedel M, Schennach-Wolff R, Musil R, Seemüller F, Spellmann I. Atypische Antipsychotika. Wie fällt der Wirksamkeitsvergleich aus? Der Neurologe und Psychiater.Sonderheft zum DGPPN-Kongress 2008; 12-18.
  • Riedel M, Spellmann I. Kognitive Störungen bei Schizophrenie und ihre Therapie. In: Möller HJ, Müller N, editors. Schizophrenie - Zukunftsperspektiven in Klinik und Forschung 2010; 205-217.
  • Bondy B, Spellmann I, Musil R, Zill P, Müller N, Möller HJ, Riedel M. Die Bedeutung der Pharmakogenetik für die antipsychotische Therapie. In: Möller HJ, Müller N (Hrsg.). Schizophrenie - Zukunftsperspektiven in Klinik und Forschung 2010; 219-228.
  • Riedel M, Musil R, Seemüller F, Spellmann I, Möller HJ, Schennach-Wolff R. Safety evaluation of zotepine for the treatment of schizophrenia. Expert Opin Drug Saf 2010 Jul;9(4):659-66. Review.
  • Schennach-Wolff R, Seemüller F, Musil R, Spellmann I, Möller HJ, Riedel M. Suicidality and outcome in schizophrenia patients. In Ritsner M (Hrsg.) Handbook of Schizophrenia and Schizophrenia Spectrum Disorders, Volume III, Therapeutic Approaches, Comorbidity, and Outcomes. Springer 2011, S. 365-383.
  • Riedel M, Seemüller F, Musil R, Spellmann I, Möller HJ, Schennach-Wolff R. Early improvement and its predictive validity in first-episode schizophrenia patients. In Ritsner M (Hrsg.) Handbook of Schizophrenia and Schizophrenia Spectrum Disorders, Volume III, Therapeutic Approaches, Comorbidity, and Outcomes. Springer 2011, S. 93-109.
  • Musil R, Spellmann I. Pharmacogenetics and cognitive symptoms in schizophrenia patients treated with antipsychotics. Pharmacogenomics. 2018 Aug 1;19(12):927-930.